Q
QuantAbundance

Notícias

Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.

31,183 signal articles · 106 in last 24h · 159,750 total before filter · latest 39m ago
106last 24h
835last 7d
118● bullish (7d)
83● bearish (7d)
214publishers
AllMacro169Earnings199M&A88Regulatory18Product15Analyst27
✕ clear all filterssentiment: neutralSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
3 Reasons Investors Watch Skyward Specialty Insurance (SKWD)
StockStory8d agoneutral
3 Reasons Investors Watch Skyward Specialty Insurance (SKWD)

Skyward Specialty Insurance has had an impressive run over the past six months as its shares have beaten the S&P 500 by 17.7%. The stock now trades at $57.18, marking a 33.9% gain. This was partly due to its solid quarterly results, and the run-up might have investors contemplating their next move.

Apple doesn't need to be in first place for AI. Here's why.
Yahoo Finance Video8d agoneutralVIDEO
Apple doesn't need to be in first place for AI. Here's why.

Apple (AAPL) stock hit a record high on Tuesday, driven by the latest fanfare over its foldable iPhone Duo. Today's Market Hang panel consists of Host Turney Duff, Yahoo Finance Executive Editor Brian Sozzi, Defiance ETFs CIO Sylvia Jablonski, Interactive Brokers chief strategist Steve Sosnick, and Gerber Kawasaki Wealth & Investment Management CEO Ross Gerber.

2 Reasons to Sell SPGI and 1 Stock to Buy Instead
StockStory8d agoneutral
2 Reasons to Sell SPGI and 1 Stock to Buy Instead

Over the last six months, S&P Global’s shares have sunk to $405.30, producing a disappointing 5.5% loss - a stark contrast to the S&P 500’s 16.2% gain. This was partly due to its softer quarterly results and may have investors wondering how to approach the situation.

Was Moderna Stock's Cancer Vaccine Run Visible In Advance?
Trefis8d agoneutral
Was Moderna Stock's Cancer Vaccine Run Visible In Advance?

Moderna (MRNA) stock rose roughly 510% over the year to September 21, 2026, climbing from about $25 to about $173. The S&P 500 gained 18.5% with dividends reinvested over the same window, and Pfizer (PFE) about 23%. The run's central event came on August 19, 2026, when Merck and Moderna said a Phase III trial of their cancer vaccine, intismeran autogene, met its endpoints in melanoma. A rough timetable for the trial was public long before the stock moved, but its result was not.

Should investors play AI bottlenecks over social media stocks?
Yahoo Finance Video8d agoneutralVIDEO
Should investors play AI bottlenecks over social media stocks?

Should investors bet more on the AI infrastructure bottlenecks than on other tech trends, such as social media? Today's Market Hang panel consists of Host Turney Duff, Yahoo Finance Executive Editor Brian Sozzi, Defiance ETFs CIO Sylvia Jablonski, Interactive Brokers chief strategist Steve Sosnick, and Gerber Kawasaki Wealth & Investment Management CEO Ross Gerber.

The AI Software Story Wall Street Is Underrating
24/7 Wall St.8d agoneutral
The AI Software Story Wall Street Is Underrating

Salesforce's agentic AI business is scaling at a pace that would make most enterprise software companies envious, yet the stock keeps getting priced like a relic from the CRM era. Something in that gap looks like an opportunity Wall Street has not yet caught up to.